Back to Search Results
Image Place holder

Amod Sarnaik, MD

★★★★★
★★★★★
4.9 (351 ratings)
Specialty: Surgery
Sub Specialty: General Surgery
Program: Cutaneous Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Skin Cancer (Nonmelanoma)

Dr. Amod Sarnaik is a surgical oncologist in the Department of Cutaneous Oncology, the Immunology Program and the Melanoma Center of Excellence at Moffitt Cancer Center.  In addition, Dr. Sarnaik holds an appointment of associate professor of oncology and surgery at the University of South Florida.Dr. Sarnaik's primary research interest involves investigation of novel immunotherapeutic treatments for melanoma.  This includes tumor-based vaccines, immune-activating antibodies, targeted inhibition of oncogenic proteins and autologous T-cell therapy. His clinical interests focus on the surgical treatment of melanoma and other cutaneous-based skin cancers, sentinel lymph node biopsy techniques, and minimizing surgically-related morbidities.Dr. Sarnaik received his undergraduate degree from Harvard University and his medical degree from the University of Michigan School of Medicine.  He completed postgraduate training at the University of Cincinnati, OH, where he served two residencies in surgery and was chief resident. He also completed a Howard Hughes investigational postdoctoral fellowship in molecular genetics, and in 2009 Dr. Sarnaik completed a surgical oncology fellowship at Moffitt Cancer Center. His research has been published in a number of professional medical journals.  


Education & Training

Board Certification:

  • Surgery - General Surgery

Fellowship:

  • University of Cincinnati - Howard Hughes Investigational Postdoctoral Fellow, Molecular Genetics
  • University of South Florida - Surgical Oncology Fellow, Moffitt Cancer Center

Residency:

  • University of Cincinnati - Surgery
  • University of Cincinnati - Surgery

Medical School:

  • University of Michigan - MD
Video Profile
Participating Trials

CLINICAL TRIAL 21707
A Proof of Concept Study of TBio-4101 (an autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) using Short-Term Cultured, Selected Autologous TIL Following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Melanoma (Phase 1)
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); TBio-4101 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Beekman KE, Parker LM, DePalo DK, Elleson KM, Sarnaik AA, Tsai KY, Withycombe BM, Zager JS. Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma. JAAD Case Rep. 2023 Mar.33:56-58. Pubmedid: 36860805. Pmcid: PMC9969237.
  • Garg SK, Sun J, Kim Y, Whiting J, Sarnaik A, Conejo-Garcia JR, Phelps M, Weber JS, Mulé JJ, Markowitz J. Dichotomous Nitric Oxide-Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma. Cancers (Basel). 2023 Mar.15(6). Pubmedid: 36980641. Pmcid: PMC10046641.
  • McClure E, Carr MJ, Patel A, Hussnain Naqvi SM, Kim Y, Harrington M, Cruse W, Gonzalez RJ, Sondak VK, Sarnaik AA, Messina JL, Zager JS. Atypical Fibroxanthoma: Outcomes from a Large Single Institution Series. Cancer Control. 2023 Jan.30. Pubmedid: 36764930. Pmcid: PMC9926370.
  • Jakub JW, Lowe M, Howard JH, Farma JM, Sarnaik A, Tuttle T, Neuman HB, Ariyan CE, Uppal A, Trocha S, Beasley GM, Wasif N, Bilimoria KY, Thomay AA, Allred JB, Chen L, Terando AM, Wayne JD, Thompson JF, Cochran AJ, Sim MS, Elashoff DE, Delman KA, Faries MB. Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). Ann Surg Oncol. 2022 Sep.29(9):5910-5920. Pubmedid: 35499783.
  • Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mule JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez C. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 May.28(9):1911-1924. Pubmedid: 35190823. Pmcid: PMC9064946.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Jakub JW, Lowe M, Harrison Howard J, Farma JM, Sarnaik A, Tuttle T, Neuman HB, Ariyan CE, Uppal A, Trocha S, Beasley GM, Wasif N, Bilimoria KY, Thomay AA, Allred JB, Chen L, Terando AM, Wayne JD, Thompson JF, Cochran AJ, Sim MS, Elashoff DE, Delman KA, Faries MB. ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II. Ann Surg Oncol. 2022 May. Pubmedid: 35552927.
  • Noyes D, Bag A, Oseni S, Semidey-Hurtado J, Cen L, Sarnaik AA, Sondak VK, Adeegbe D. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells. J Immunother Cancer. 2022 May.10(5). Pubmedid: 35618289. Pmcid: PMC9125763.
  • Saif A, Rossi AJ, Sarnaik A, Hernandez JM, Zager JS. Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM). Ann Surg Oncol. 2022 Jun.29(6):3377-3378. Pubmedid: 35229218.
  • Mullinax JE, Egger ME, McCarter M, Monk BJ, Toloza EM, Brousseau S, Jagasia M, Sarnaik A. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Cancer J. 2022 Jul.28(4):285-293. Pubmedid: 35880938. Pmcid: PMC9335895.
  • Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, O'shea K, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Hotz M, Farma JM, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley GM, Hui JYC, Been L, Kruijff S, Sinco B, Sarnaik AA, Sondak VK, Zager JS, Dossett LA. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node Positive Melanoma at Major Referral Centers. Ann Surg. 2022 Jan. Pubmedid: 35129464.
  • Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, van Akkooi ACJ, Ollila DW, Collichio F, Zager JS. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Ann Surg Oncol. 2022 Feb.29(2):791-801. Pubmedid: 34648098.
  • Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, van Akkooi ACJ, Ollila DW, Collichio F, Zager JS. ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. Ann Surg Oncol. 2022 Feb.29(2):804-805. Pubmedid: 34817772.
  • Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mule JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022 Dec.28(24):5317-5329. Pubmedid: 36215121.
  • Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts. J Immunother Cancer. 2022 Dec.10(12). Pubmedid: 36600653. Pmcid: PMC9748991.
  • Betof-Warner A, Sullivan RJ, Sarnaik A. Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View. Am Soc Clin Oncol Educ Book. 2022 Apr.42:1-8. Pubmedid: 35561301.
  • Broman KK, Bettampadi D, Pérez-Morales J, Sun J, Kirichenko D, Carr MJ, Eroglu Z, Tarhini AA, Khushalani N, Schabath MB, Sarnaik A, Sondak VK, Zager JS. Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. Ann Surg Oncol. 2021 Nov.28(12):6978-6985. Pubmedid: 34363118. Pmcid: PMC8828269.
  • Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 May.94:107481. Pubmedid: 33636562. Pmcid: PMC8205103.
  • Innamarato P, Morse J, Mackay A, Asby S, Beatty M, Blauvelt J, Kidd S, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors. BMC Cancer. 2021 Jun.21(1):756. Pubmedid: 34187428. Pmcid: PMC8243723.
  • Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021 Jul.127(13):2251-2261. Pubmedid: 33826754. Pmcid: PMC8764513.
  • Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 Jul.27(14):4109-4125. Pubmedid: 34035069. Pmcid: PMC8282775.
  • Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik AA. Cardiovascular Toxicity and Mortality Associated With Adoptive Cell Therapy and Tumor-infiltrating Lymphocytes for Advanced Stage Melanoma. J Immunother. 2021 Feb.44(2):86-89. Pubmedid: 33044384.
  • Mullinax JE, Hall M, Beatty M, Weber AM, Sannasardo Z, Svrdlin T, Hensel J, Richards A, Gonzalez RJ, Cox CA, Kelley L, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. J Immunother. 2021 Feb.44(2):63-70. Pubmedid: 33443972. Pmcid: PMC8111686.
  • Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021 Feb.12:628063. Pubmedid: 33717150. Pmcid: PMC7949015.
  • Broman KK, Bettampadi D, Pérez-Morales J, Sun J, Kirichenko D, Carr MJ, Eroglu Z, Tarhini AA, Khushalani N, Schabath MB, Sarnaik A, Sondak VK, Zager JS. ASO Visual Abstract: Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. Ann Surg Oncol. 2021 Dec.28(Suppl 3):678-679. Pubmedid: 34471988.
  • Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 Aug.39(24):2656-2666. Pubmedid: 33979178. Pmcid: PMC8376325.
  • Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
  • Innamarato P, Kodumudi K, Asby S, Schachner B, Hall M, Mackay A, Wiener D, Beatty M, Nagle L, Creelan BC, Sarnaik AA, Pilon-Thomas S. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Mol Ther. 2020 Oct.28(10):2252-2270. Pubmedid: 32615068. Pmcid: PMC7544980.
  • Innamarato P, Asby S, Morse J, Mackay A, Hall M, Kidd S, Nagle L, Sarnaik AA, Pilon-Thomas S. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells. J Immunol. 2020 Nov.205(10):2893-2904. Pubmedid: 33020146. Pmcid: PMC7741883.
  • Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J. Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell Melanoma Res. 2020 Jan.33(1):86-95. Pubmedid: 31329344. Pmcid: PMC6928428.
  • Garg SK, Ott MJ, Mostofa AGM, Chen Z, Chen YA, Kroeger J, Cao B, Mailloux AW, Agrawal A, Schaible BJ, Sarnaik A, Weber JS, Berglund AE, Mulé JJ, Markowitz J. Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy. Front Immunol. 2020 Feb.11:164. Pubmedid: 32161584. Pmcid: PMC7052497.
  • Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Clin Cancer Res. 2019 May.25(9):2783-2794. Pubmedid: 30765391. Pmcid: PMC6497575.
  • Rothermel LD, Sarnaik AA, Khushalani NI, Sondak VK. Current Immunotherapy Practices in Melanoma. Surg Oncol Clin N Am. 2019 Jul.28(3):403-418. Pubmedid: 31079796.
  • Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J, Cruse CW, Gonzalez RJ, Sarnaik AA, Sondak VK, Wuthrick EJ, Harrison LB, Zager JS. Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. Ann Surg Oncol. 2019 Feb.26(2):379-385. Pubmedid: 30311164. Pmcid: PMC7771265.
  • Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, Ren Y, Fang B, Yoder S, Kim S, Wan L, Sarnaik AA, Koomen JM, Messina JL, Teer JK, Kim Y, Wu J, Chalfant CE, Kim M. PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas. Mol Cancer Res. 2019 Feb.17(2):583-593. Pubmedid: 30355677. Pmcid: PMC6386183.
  • Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics. J Immunother Cancer. 2019 Feb.7(1):33. Pubmedid: 30728070. Pmcid: PMC6366050.
  • Louie RJ, Perez MC, Jajja MR, Sun J, Collichio F, Delman KA, Lowe M, Sarnaik AA, Zager JS, Ollila DW. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. J Am Coll Surg. 2019 Apr.228(4):644-649. Pubmedid: 30690076.
  • Miura JT, Dossett LA, Thapa R, Kim Y, Potdar A, Daou H, Sun J, Sarnaik AA, Zager JS. Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes. Ann Surg Oncol. 2019 Apr.27(1):196-202. Pubmedid: 30949862. Pmcid: PMC7771311.
  • Weitman ES, Perez MC, Lee D, Kim Y, Fulp W, Sondak VK, Sarnaik AA, Gonzalez RJ, Cruse CW, Messina JL, Zager JS. Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins. Melanoma Manag. 2019 Apr.6(2):MMT17. Pubmedid: 31406562. Pmcid: PMC6688556.
  • Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?. Ann Surg Oncol. 2018 Oct.25(11):3334-3340. Pubmedid: 30073600. Pmcid: PMC7771268.
  • Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar.8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
  • Oliver DE, Sondak VK, Strom T, Zager JS, Naghavi AO, Sarnaik A, Messina JL, Caudell JJ, Trotti AM, Torres-Roca JF, Khushalani NI, Harrison LB. Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Manag. 2018 Jun.5(1):MMT02. Pubmedid: 30190928. Pmcid: PMC6122528.
  • Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul.7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
  • Perez MC, Miura JT, Naqvi SMH, Kim Y, Holstein A, Lee D, Sarnaik AA, Zager JS. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Ann Surg Oncol. 2018 Dec.25(13):3960-3965. Pubmedid: 30298318. Pmcid: PMC7771271.
  • Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. PLoS One. 2018 Apr.13(4):e0196033. Pubmedid: 29694419. Pmcid: PMC5918896.
  • Glazer ES, Porubsky CF, Francis JD, Ibanez J, Castner N, Messina JL, Sarnaik AA, Harrington MA, Cruse CW, Sondak VK, Zager JS. Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions. Ann Plast Surg. 2017 Jun.78(6):663-667. Pubmedid: 27984218. Pmcid: PMC5425303.
  • Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Grotz TE, Allred JB, Suman VJ, Brady MS, Tyler D, Wayne JD, Nelson H. Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial. Ann Surg. 2017 Jan.265(1):192-196. Pubmedid: 28009745. Pmcid: PMC4999343.
  • Doepker MP, Yamamoto M, Applebaum MA, Patel NU, Jaime Montilla-Soler M, Sarnaik AA, Wayne Cruse C, Sondak VK, Zager JS. Comparison of Single-Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies. Ann Surg Oncol. 2017 Feb.24(2):355-361. Pubmedid: 27660259. Pmcid: PMC5955617.
  • Mahajan NP, Malla P, Bhagwat S, Sharma V, Sarnaik A, Kim J, Pilon-Thomas S, Weber J, Mahajan K. WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of gene expression. Oncotarget. 2017 Dec.8(63):106352-106368. Pubmedid: 29290954. Pmcid: PMC5739739.
  • Zendejas B, Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Tyler D, Brady MS, Farley DR. Laparoscopic skill assessment of practicing surgeons prior to enrollment in a surgical trial of a new laparoscopic procedure. Surg Endosc. 2017 Aug.31(8):3313-3319. Pubmedid: 27928664. Pmcid: PMC6201269.
  • Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. J Natl Compr Canc Ne. 2017 Apr.15(4):473-482. Pubmedid: 28404758. Pmcid: PMC7771284.
  • Sarnaik AA, Zager JS, Sondak VK. Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma. Oncology (Williston Park). 2016 Oct.30(10):891-2-895. Pubmedid: 27753054.
  • Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 2016 Oct.4:61. Pubmedid: 27777771. Pmcid: PMC5067894.
  • Lienlaf M, Perez-Villarroel P, Knox T, Pabon M, Sahakian E, Powers J, Woan KV, Lee C, Cheng F, Deng S, Smalley KS, Montecino M, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Seto E, Weber J, Sotomayor EM, Villagra A. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol. 2016 May.10(5):735-750. Pubmedid: 26775640. Pmcid: PMC4870131.
  • Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Jake Allred JB, Suman VJ, Grotz TE, Zendejas B, Wayne JD, Tyler DS. Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. J Am Coll Surg. 2016 Mar.222(3):253-260. Pubmedid: 26711792. Pmcid: PMC5012184.
  • Liu H, Innamarato PP, Kodumudi K, Weber A, Nemoto S, Robinson JL, Crago G, McCardle T, Royster E, Sarnaik AA, Pilon-Thomas S. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget. 2016 Jun.7(25):37893-37905. Pubmedid: 27177220. Pmcid: PMC5122358.
  • Doepker MP, Thompson ZJ, Fisher KJ, Yamamoto M, Nethers KW, Harb JN, Applebaum MA, Gonzalez RJ, Sarnaik AA, Messina JL, Sondak VK, Zager JS. Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?. Ann Surg Oncol. 2016 Jul.23(7):2336-2342. Pubmedid: 26957503. Pmcid: PMC4904729.
  • Doepker MP, Thompson ZJ, Harb JN, Messina JL, Puleo CA, Egan KM, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS. Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy. J Surg Oncol. 2016 Jan.113(1):98-102. Pubmedid: 26661407. Pmcid: PMC4904728.
  • Sloot S, Rashid OM, Sarnaik AA, Zager JS. Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control. 2016 Jan.23(1):12-20. Pubmedid: 27009452. Pmcid: PMC4904721.
  • Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Grotz TE, Allred JB, Suman VJ, Brady MS, Tyler D, Wayne JD, Nelson H. Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial. Ann Surg. 2016 Feb. Pubmedid: 26918640.
  • Dossett LA, Castner NB, Pow-Sang JM, Abbott AM, Sondak VK, Sarnaik AA, Zager JS. Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. J Am Coll Surg. 2016 Apr.222(4):702-709. Pubmedid: 26875071. Pmcid: PMC4871144.
  • Sung H, Kanchi KL, Wang X, Hill KS, Messina JL, Lee JH, Kim Y, Dees ND, Ding L, Teer JK, Yang S, Sarnaik AA, Sondak VK, Mulé JJ, Wilson RK, Weber JS, Kim M. Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget. 2016 Apr.7(17):23885-23896. Pubmedid: 26993606. Pmcid: PMC5029671.
  • Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S. Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy. PLoS One. 2016 Apr.11(4):e0153053. Pubmedid: 27050669. Pmcid: PMC4822778.
  • Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, Schell MJ, DeConti RC, Messina JL, Sondak VK, Zager JS. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. Cancer. 2015 Sep.121(18):3252-3260. Pubmedid: 26038193. Pmcid: PMC4904725.
  • Yamamoto M, Fisher KJ, Wong JY, Koscso JM, Konstantinovic MA, Govsyeyev N, Messina JL, Sarnaik AA, Cruse CW, Gonzalez RJ, Sondak VK, Zager JS. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer. 2015 May.121(10):1628-1636. Pubmedid: 25677366. Pmcid: PMC4515965.
  • Han D, Han G, Zhao X, Rao NG, Messina JL, Marzban SS, Sarnaik AA, Cruse CW, Sondak VK, Zager JS. Clinicopathologic predictors of survival in patients with desmoplastic melanoma. PLoS One. 2015 Mar.10(3):e0119716. Pubmedid: 25811671. Pmcid: PMC4374691.
  • Chacon JA, Sarnaik AA, Pilon-Thomas S, Radvanyi L. Triggering co-stimulation directly in melanoma tumor fragments drives CD8+ tumor-infiltrating lymphocyte expansion with improved effector-memory properties. Oncoimmunology. 2015 Jul.4(12):e1040219. Pubmedid: 26587314. Pmcid: PMC4635692.
  • Chacon J, Sarnaik A, Chen J, Creasy C, Kale C, Robinson J, Weber J, Hwu P, Pilon-Thomas S, Radvanyi LG. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clin Cancer Res. 2015 Feb.21(3):611-621. Pubmedid: 25472998. Pmcid: PMC4315752.
  • Woods DM, Sodré AL, Sarnaik AA, Villagra A, Sotomayor EM, Weber J. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res. 2015 Dec.3(12):1375-1385. Pubmedid: 26297712. Pmcid: PMC4674300.
  • Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KS, Bergman J, Seto E, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Celis E, Weber J, Sotomayor EM, Villagra A. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015 Aug.9(7):1447-1457. Pubmedid: 25957812. Pmcid: PMC4523430.
  • Sun J, Lu F, He H, Shen J, Messina J, Mathew R, Wang D, Sarnaik AA, Chang WC, Kim M, Cheng H, Yang S. STIM1- and Orai1-mediated Ca(2+) oscillation orchestrates invadopodium formation and melanoma invasion. J Cell Biol. 2014 Nov.207(4):535-548. Pubmedid: 25404747. Pmcid: PMC4242838.
  • Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 2014 Mar.8(7):e68561. Pubmedid: 23874673. Pmcid: PMC3714270.
  • Rebecca VW, Wood ER, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics. 2014 Jul.13(7):1844-1854. Pubmedid: 24760959. Pmcid: PMC4083119.
  • Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013 Sep.8(4):e60031. Pubmedid: 23560068. Pmcid: PMC3613355.
  • Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2013 Sep.2(9):e25581. Pubmedid: 24319633. Pmcid: PMC3850170.
  • Radvanyi L, Pilon-Thomas S, Peng W, Sarnaik A, Mulé JJ, Weber J, Hwu P. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter. Clin Cancer Res. 2013 Oct.19(19):5541. Pubmedid: 24048330. Pmcid: PMC3823378.
  • Zager JS, Sarnaik AA, Gibney GT, Kudchadkar RR. Recent advances in the treatment of melanoma. Cancer Control. 2013 Oct.20(4):244-245. Pubmedid: 24077400.
  • Deneve JL, Turaga KK, Marzban SS, Puleo CA, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS. Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. Am Surg. 2013 May.79(5):476-482. Pubmedid: 23635582. Pmcid: PMC4505800.
  • Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013 Mar.14(3):211-220. Pubmedid: 23354483. Pmcid: PMC3578019.
  • Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G, Sarnaik AA, Pilon-Thomas S. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immun. 2013 Jun.62(6):1083-1091. Pubmedid: 23604104. Pmcid: PMC3666559.
  • Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA. Immunotherapy for gastrointestinal malignancies. Cancer Control. 2013 Jan.20(1):32-42. Pubmedid: 23302905. Pmcid: PMC4761871.
  • Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec.31(34):4311-4318. Pubmedid: 24145345. Pmcid: PMC3837092.
  • Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, Wayne Cruse C, Sarnaik AA, Puleo C, Sondak VK, Zager JS. Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Ann Surg Oncol. 2012 Oct.19(11):3335-3342. Pubmedid: 22766986. Pmcid: PMC4504019.
  • Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012 Oct.35(8):615-620. Pubmedid: 22996367. Pmcid: PMC4467830.
  • Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012 Nov.19(12):3888-3895. Pubmedid: 22864798. Pmcid: PMC4519977.
  • Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May.18(9):2502-2514. Pubmedid: 22351686. Pmcid: PMC3398738.
  • Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med. 2012 Jul.10:146. Pubmedid: 22788688. Pmcid: PMC3527361.
  • Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol. 2012 Dec.189(11):5147-5154. Pubmedid: 23100512. Pmcid: PMC3505990.
  • Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011 Feb.17(4):896-906. Pubmedid: 21106722. Pmcid: PMC3041838.
  • Sondak VK, Sarnaik AA. Minimizing Morbidity while Preserving Outcome after Inguinal Lymphadenectomy: Navigating between Scylla and Charybdis. Ann Surg Oncol. 2011 Apr.18(4):909-911. Pubmedid: 21246401.
  • Sarnaik AA, Meade T, King J, Acs G, Hoover S, Cox CE, Carter WB, Laronga C. Adenoid cystic carcinoma of the breast: a review of a single institution's experience. Breast J. 2010 May.16(2):208-210. Pubmedid: 20030648.
  • Sarnaik AA, Zager JS, Cox LE, Ochoa TM, Messina JL, Sondak VK. Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma <= 1 cm Is Not Justified. J Clin Oncol. 2010 Jan.28(1):e7-e7. Pubmedid: 19933899.
  • Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 2009 May.15(3):169-173. Pubmedid: 19556898.
  • Sarnaik AA, Puleo CA, Zager JS, Sondak VK. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control. 2009 Jul.16(3):240-247. Pubmedid: 19556964.
  • Qian J, Sarnaik AA, Bonney TM, Keirsey J, Combs KA, Steigerwald K, Acharya S, Behbehani GK, Barton MC, Lowy AM, Groden J. The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology. 2008 Jul.135(1):152-162. Pubmedid: 18474248. Pmcid: PMC2832605.
  • Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep. 2007 Sep.9(5):417-427. Pubmedid: 17706171.
  • Sarnaik AA, Saad AG, Mutema GK, Martin SP, Attar A, Lowy AM. Osteoclast-like giant cell tumor of the pancreas associated with a mucinous cystadenocarcinoma. Surgery. 2003 Jun.133(6):700-701. Pubmedid: 12796742.
  • Sarnaik AA, Sussman JJ, Ahmad SA, Lowy AM. Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. Surg Oncol Clin N Am. 2003 Jul.12(3):849-863. Pubmedid: 14567036.
  • Sarnaik AA, Lien MH, Nghiem P, Bichakjian CK. Clinical recognition, diagnosis, and staging of merkel cell carcinoma, and the role of the multidisciplinary management team. Curr Prob Cancer. 34(1):38-46. Pubmedid: 20371073. Pmcid: PMC9479021.

Patient Comments
Overall Satisfaction
4.9
★★★★★
★★★★★

351 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments